Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial

The National Institutes of Health/National Institute of Allergy and Infectious Diseases. <b>Registration for the COVE Trial. </b> ClinicalTrials.gov ID# NCT04470427.

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2024-11-25
DOI
https://doi.org/10.1093/ofid/ofae689
Citations
7
Primary Topic
COVID-19 Clinical Research Studies
Type
article
Field-Weighted Citation Impact
2.72

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial

Weiping Deng, Haiyu Zhou, Avika Dixit, Hana M. El Sahly et al.
7 citations
Open Forum Infectious Diseases
COVID-19 Clinical Research Studies
2.72
article

Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial

Weiping Deng, Haiyu Zhou, Avika Dixit, Hana M. El Sahly, Eric Chun‐Pu Chu, Joanne E. Tomassini, Jacqueline Miller, Frances Priddy, Holly Janes, Dean A. Follmann, Megan A Berman, Ian Frank, Colleen F. Kelley, Peter B. Gilbert, Lindsey Robert Baden, Xiaowei Wang, Rituparna Das, Brandon Essink
article en
7 citations

Abstract

The National Institutes of Health/National Institute of Allergy and Infectious Diseases. <b>Registration for the COVE Trial. </b> ClinicalTrials.gov ID# NCT04470427.

Open Forum Infectious DiseasesVol. 11(12)
Brigham and Women's Hospital (US), Grady Memorial Hospital (US), Harvard University (US), Emory University (US), Baylor College of Medicine (US), Fred Hutch Cancer Center (US), Grady Health System (US), Moderna Therapeutics (United States) (US), National Institute of Allergy and Infectious Diseases (US), Meridian Clinical Research (US), The University of Texas Medical Branch at Galveston (US), University of Pennsylvania (US)
National Institutes of Health, National Institute of Allergy and Infectious Diseases
Openalex Percentile: Top 9%
COVID-19 Clinical Research Studies
2.72
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.